126 related articles for article (PubMed ID: 15377855)
1. The experimental antitumor agents Phortress and doxorubicin are equiactive against human-derived breast carcinoma xenograft models.
Fichtner I; Monks A; Hose C; Stevens MF; Bradshaw TD
Breast Cancer Res Treat; 2004 Sep; 87(1):97-107. PubMed ID: 15377855
[TBL] [Abstract][Full Text] [Related]
2. In vitro, in vivo, and in silico analyses of the antitumor activity of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazoles.
Leong CO; Suggitt M; Swaine DJ; Bibby MC; Stevens MF; Bradshaw TD
Mol Cancer Ther; 2004 Dec; 3(12):1565-75. PubMed ID: 15634650
[TBL] [Abstract][Full Text] [Related]
3. Antitumour 2-(4-aminophenyl)benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo.
Leong CO; Gaskell M; Martin EA; Heydon RT; Farmer PB; Bibby MC; Cooper PA; Double JA; Bradshaw TD; Stevens MF
Br J Cancer; 2003 Feb; 88(3):470-7. PubMed ID: 12569393
[TBL] [Abstract][Full Text] [Related]
4. Preclinical toxicokinetic evaluation of phortress [2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole lysylamide dihydrochloride] in two rodent species.
Bradshaw TD; Wren JE; Bruce M; Barrett DA; Leong CO; Gaskell M; Wright EK; Farmer PB; Henderson CJ; Wolf R; Stevens MF
Pharmacology; 2009; 83(2):99-109. PubMed ID: 19088497
[TBL] [Abstract][Full Text] [Related]
5. The development of the antitumour benzothiazole prodrug, Phortress, as a clinical candidate.
Bradshaw TD; Westwell AD
Curr Med Chem; 2004 Apr; 11(8):1009-21. PubMed ID: 15078163
[TBL] [Abstract][Full Text] [Related]
6. Induction of CYP1A1 in tumor cells by the antitumor agent 2-[4-amino-3-methylphenyl]-5-fluoro-benzothiazole: a potential surrogate marker for patient sensitivity.
Hose CD; Hollingshead M; Sausville EA; Monks A
Mol Cancer Ther; 2003 Dec; 2(12):1265-72. PubMed ID: 14707267
[TBL] [Abstract][Full Text] [Related]
7. DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells.
Trapani V; Patel V; Leong CO; Ciolino HP; Yeh GC; Hose C; Trepel JB; Stevens MF; Sausville EA; Loaiza-Pérez AI
Br J Cancer; 2003 Feb; 88(4):599-605. PubMed ID: 12592376
[TBL] [Abstract][Full Text] [Related]
8. Fluorinated 2-(4-amino-3-methylphenyl)benzothiazoles induce CYP1A1 expression, become metabolized, and bind to macromolecules in sensitive human cancer cells.
Brantley E; Trapani V; Alley MC; Hose CD; Bradshaw TD; Stevens MF; Sausville EA; Stinson SF
Drug Metab Dispos; 2004 Dec; 32(12):1392-401. PubMed ID: 15355884
[TBL] [Abstract][Full Text] [Related]
9. BRCA1 modulates sensitivity to 5F-203 by regulating xenobiotic stress-inducible protein levels and EROD activity.
Kang HJ; Kim HJ; Kwon SH; Kang BD; Eling TE; Lee SH; Bae I
Cancer Chemother Pharmacol; 2008 Sep; 62(4):689-97. PubMed ID: 18074135
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl)benzothiazoles.
Bradshaw TD; Bibby MC; Double JA; Fichtner I; Cooper PA; Alley MC; Donohue S; Stinson SF; Tomaszewjski JE; Sausville EA; Stevens MF
Mol Cancer Ther; 2002 Feb; 1(4):239-46. PubMed ID: 12467219
[TBL] [Abstract][Full Text] [Related]
11. Role of Cyp1A1 in modulation of antitumor properties of the novel agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) in human breast cancer cells.
Chua MS; Kashiyama E; Bradshaw TD; Stinson SF; Brantley E; Sausville EA; Stevens MF
Cancer Res; 2000 Sep; 60(18):5196-203. PubMed ID: 11016648
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces single-strand breaks and DNA-protein cross-links in sensitive MCF-7 breast cancer cells.
Brantley E; Antony S; Kohlhagen G; Meng L; Agama K; Stinson SF; Sausville EA; Pommier Y
Cancer Chemother Pharmacol; 2006 Jul; 58(1):62-72. PubMed ID: 16331501
[TBL] [Abstract][Full Text] [Related]
13. Protein Encapsulation of Experimental Anticancer Agents 5F 203 and Phortress: Towards Precision Drug Delivery.
Breen AF; Scurr D; Cassioli ML; Wells G; Thomas NR; Zhang J; Turyanska L; Bradshaw TD
Int J Nanomedicine; 2019; 14():9525-9534. PubMed ID: 31824148
[TBL] [Abstract][Full Text] [Related]
14. CYP2S1 and CYP2W1 mediate 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW-610, NSC 721648) sensitivity in breast and colorectal cancer cells.
Tan BS; Tiong KH; Muruhadas A; Randhawa N; Choo HL; Bradshaw TD; Stevens MF; Leong CO
Mol Cancer Ther; 2011 Oct; 10(10):1982-92. PubMed ID: 21831963
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of acquired resistance to 2-(4-Amino-3-methylphenyl)benzothiazole in breast cancer cell lines.
Bradshaw TD; Stone EL; Trapani V; Leong CO; Matthews CS; te Poele R; Stevens MF
Breast Cancer Res Treat; 2008 Jul; 110(1):57-68. PubMed ID: 17674193
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of some new benzoxazole derivatives and investigation of their anticancer activities.
Osmaniye D; Korkut Çelikateş B; Sağlık BN; Levent S; Acar Çevik U; Kaya Çavuşoğlu B; Ilgın S; Özkay Y; Kaplancıklı ZA
Eur J Med Chem; 2021 Jan; 210():112979. PubMed ID: 33183865
[TBL] [Abstract][Full Text] [Related]
17. Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity.
Devy L; de Groot FM; Blacher S; Hajitou A; Beusker PH; Scheeren HW; Foidart JM; Noël A
FASEB J; 2004 Mar; 18(3):565-7. PubMed ID: 14734647
[TBL] [Abstract][Full Text] [Related]
18. In vitro cytotoxicity of Phortress against colorectal cancer.
Mukherjee A; Martin SG
Int J Oncol; 2006 Nov; 29(5):1287-94. PubMed ID: 17016663
[TBL] [Abstract][Full Text] [Related]
19. CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.
Dubois V; Dasnois L; Lebtahi K; Collot F; Heylen N; Havaux N; Fernandez AM; Lobl TJ; Oliyai C; Nieder M; Shochat D; Yarranton GT; Trouet A
Cancer Res; 2002 Apr; 62(8):2327-31. PubMed ID: 11956091
[TBL] [Abstract][Full Text] [Related]
20. Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates.
Trail PA; Willner D; Knipe J; Henderson AJ; Lasch SJ; Zoeckler ME; TrailSmith MD; Doyle TW; King HD; Casazza AM; Braslawsky GR; Brown J; Hofstead SJ; Greenfield RS; Firestone RA; Mosure K; Kadow KF; Yang MB; Hellström KE; Hellström I
Cancer Res; 1997 Jan; 57(1):100-5. PubMed ID: 8988048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
